Anebulo Pharmaceuticals, Inc. (ANEB)
NASDAQ: ANEB · Real-Time Price · USD
1.360
-0.040 (-2.86%)
Mar 28, 2025, 4:00 PM EDT - Market closed

Anebulo Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20
Selling, General & Admin
4.254.766.183.871.340.14
Research & Development
3.753.555.62.962.270.9
Operating Expenses
88.3111.786.833.611.04
Operating Income
-8-8.31-11.78-6.83-3.61-1.04
Interest Expense
-0.24-0.15---0.01-0.01
Interest & Investment Income
0.150.250.090.010-
Other Non Operating Income (Expenses)
0.430.01-0.04-0-26.63-
Pretax Income
-7.67-8.2-11.73-6.83-30.25-1.05
Net Income
-7.67-8.2-11.73-6.83-30.25-1.05
Preferred Dividends & Other Adjustments
----8.21-
Net Income to Common
-7.67-8.2-11.73-6.83-38.46-1.05
Shares Outstanding (Basic)
262625231412
Shares Outstanding (Diluted)
262625231412
Shares Change (YoY)
2.48%2.98%7.41%71.49%13.44%-
EPS (Basic)
-0.29-0.32-0.47-0.29-2.83-0.09
EPS (Diluted)
-0.29-0.32-0.47-0.29-2.83-0.09
EBIT
-8-8.31-11.78-6.83-3.61-1.04
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q